The Journal of Allergy and Clinical Immunology: In Practice
Original ArticleDiagnostic Utility of Urinary LTE4 in Asthma, Allergic Rhinitis, Chronic Rhinosinusitis, Nasal Polyps, and Aspirin Sensitivity
Section snippets
Study design
This was a retrospective study of all subjects who underwent measurement of 24-hour urinary LTE4 at our institution between March 2014 and April 2015. The study was approved by the institutional review board of the Mayo Clinic.
Subjects and diagnosis
All patients who underwent LTE4 testing were selected for analysis from a laboratory list. Patients' charts were reviewed for the diagnoses after completion of care and visit to ensure only final diagnoses were considered for analyses. Patients who were found to have mast
Characteristics of subjects in the study
The characteristics of the patients included in the study are presented in Table I. The criteria for inclusion of controls are presented in Table E1 and objective data related to the respiratory diagnoses of asthma, allergic rhinitis, and CRS are presented in Table E2 in this article's Online Repository at www.jaci-inpractice.org. Of the 194 patients in the study, females comprised 60% of the study population. Sixty-two patients (31.9%) in the study carried a respiratory-related diagnosis that
Discussion
LTE4 is a stable end product of the cystinyl leukotriene pathway and its measurement in urine as a biomarker of activity of this metabolic pathway is well validated. Increased LTE4 excretion has been demonstrated in allergen-induced asthma, asthma exacerbations, aspirin challenge, and increased basal excretion in AERD.11, 12, 13, 17, 18, 19 In this study, we wished to determine the diagnostic utility of 24-hour urinary LTE4 based on established and derived values. Because aspirin sensitivity
References (26)
How patient experiences should change our approach to treating patients with aspirin-exacerbated respiratory disease
J Allergy Clin Immunol Pract
(2015)- et al.
Symptom-based clustering in chronic rhinosinusitis relates to history of aspirin sensitivity and postsurgical outcomes
J Allergy Clin Immunol Pract
(2015) - et al.
Survey-defined patient experiences with aspirin-exacerbated respiratory disease
J Allergy Clin Immunol Pract
(2015) - et al.
An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease
J Allergy Clin Immunol
(2008) - et al.
Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2005) - et al.
Asthma outcomes: biomarkers
J Allergy Clin Immunol
(2012) - et al.
Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes
Blood
(2012) - et al.
Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma
J Allergy Clin Immunol
(1995) - et al.
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study
J Allergy Clin Immunol
(2014) - et al.
Immunoaffinity resin for purification of urinary leukotriene E4
Prostaglandins Other Lipid Mediat
(1998)
The diagnostic odds ratio: a single indicator of test performance
J Clin Epidemiol
Increased leukotriene E4 excretion in systemic mastocytosis
Prostaglandins Other Lipid Mediat
Chronic rhinosinusitis: more than just “asthma of the upper airway”
Am J Respir Crit Care Med
Cited by (0)
Mayo Clinic Foundation supported this study.
Conflicts of interest: R. Divekar is employed by Mayo Clinic and has an unrelated web blog through Google.com. J. Hagan has received research support from the National Institutes of Health, GlaxoSmithKline, AstraZeneca, MedImmune, and Teva. M. Park has received consultancy fees from Baxter as an advisory board member. J. Butterfield declares that he has received licensing payments by pharmaceutical companies using HMC-1.1 and HMC-1.2 cell lines obtained from our laboratory. The rest of the authors declare that they have no relevant conflicts of interest.